Ontology highlight
ABSTRACT: Purpose
To examine the association of baseline body mass index (BMI) with the risk of recurrence or death in postmenopausal women with early-stage breast cancer receiving adjuvant tamoxifen or letrozole in the Breast International Group (BIG) 1-98 trial at 8.7 years of median follow-up.Patients and methods
This report analyzes 4,760 patients with breast cancer randomly assigned to 5 years of monotherapy with letrozole or tamoxifen in the BIG 1-98 trial with available information on BMI at randomization. Multivariable Cox modeling assessed the association of BMI with disease-free survival, overall survival (OS), breast cancer-free interval, and distant recurrence-free interval and tested for treatment-by-BMI interaction. Median follow-up was 8.7 years.Results
Seventeen percent of patients have died. Obese patients (BMI ≥ 30 kg/m(2)) had slightly poorer OS (hazard ratio [HR] = 1.19; 95% CI, 0.99 to 1.44) than patients with normal BMI (< 25 kg/m(2)), whereas no trend in OS was observed in overweight (BMI 25 to < 30 kg/m(2)) versus normal-weight patients (HR = 1.02; 95% CI, 0.86 to 1.20). Treatment-by-BMI interactions were not statistically significant. The HRs for OS comparing obese versus normal BMI were HR = 1.22 (95% CI, 0.93 to 1.60) and HR = 1.18 (95% CI, 0.91 to 1.52) in the letrozole and tamoxifen groups, respectively.Conclusion
There was no evidence that the benefit of letrozole over tamoxifen differed according to patients' BMI.
SUBMITTER: Ewertz M
PROVIDER: S-EPMC3488270 | biostudies-literature | 2012 Nov
REPOSITORIES: biostudies-literature
Ewertz Marianne M Gray Kathryn P KP Regan Meredith M MM Ejlertsen Bent B Price Karen N KN Thürlimann Beat B Bonnefoi Hervé H Forbes John F JF Paridaens Robert J RJ Rabaglio Manuela M Gelber Richard D RD Colleoni Marco M Láng István I Smith Ian E IE Coates Alan S AS Goldhirsch Aron A Mouridsen Henning T HT
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20121008 32
<h4>Purpose</h4>To examine the association of baseline body mass index (BMI) with the risk of recurrence or death in postmenopausal women with early-stage breast cancer receiving adjuvant tamoxifen or letrozole in the Breast International Group (BIG) 1-98 trial at 8.7 years of median follow-up.<h4>Patients and methods</h4>This report analyzes 4,760 patients with breast cancer randomly assigned to 5 years of monotherapy with letrozole or tamoxifen in the BIG 1-98 trial with available information ...[more]